BACKGROUND:

The prevalence of inflammatory bowel disease is estimated to be 0.7% in western countries. Its association with pregnancy is constantly being studied and updated. This disease is associated with several obstetric conditions: prematurity or increased teratogenicity. Medical care and treatment during pregnancy is a challenge.

OBJECTIVE:

To update the knowledge on how pregnancy modifies the course of the disease and how the disease modifies the course of the disease, to mention the safety of treatments for pregnant women and the current obstetric consensus.

METHOD:

Literature search in two databases (PubMed and Embase) with the following search criteria (MeSH): "inflammatory bowel disease" and "pregnancy" of articles published between 2015 and December 2022, written in all languages: meta-analyses, clinical trials, systematic reviews, narratives, prospective and retrospective studies.

RESULTS:

345 records were identified and, after elimination of duplicates and other causes, 30 articles were selected for relevance and novelty.

CONCLUSION:

The pregnant patient with inflammatory bowel disease should be considered high risk and require close follow-up. Pregnancy planning is essential to optimise disease activity and minimise complications. Although most drugs used to treat inflammatory bowel disease.